Biotech Values

[Biowatch]

"I was/am familiar with vascepa MoA before you are born! (If you are <30Y old) "

Can you tell me more about the method of action?

I admit, I am over thirty years old, but I don't understand how it works.

Could you please supply me with the details you know so well?

Thank you very much in advance.

I know that cod liver oil, which contains a great deal of omega-3 fatty acids and vitamin D is good for your health.

Which is why the phrase "a spoonful of cod liver oil" has been a folk health supplement for centuries...
https://en.wikipedia.org/wiki/Cod_liver_oil

As to the Vascepa MoA, I looked at Wiki:

[vascepa aka Eicosapentaenoic acid ethyl ester; Ethyl eicosapentaenoate; Eicosapent...]

https://en.wikipedia.org/wiki/Ethyl_eicosapentaenoic_acid

Ethyl eicosapentaenoic acid (E-EPA, icosapent ethyl) is a medication used to treat hypertriglyceridemia. It is used in combination with changes in diet in adults with hypertriglyceridemia ≥ 150 mg/dL.[2]
It is made from the omega-3 fatty acid eicosapentaenoic acid (EPA).[2] The US Food and Drug Administration (FDA) granted the approval of it (as Vascepa) in 2012, to Amarin Corporation, and it became the second fish oil-based medication after omega-3 acid ethyl esters, brand named Lovaza, which was approved in 2004.[3] On 13 December 2019, FDA also approved it as the first drug specifically "to reduce cardiovascular risk among patients with elevated triglyceride levels".[2]

...Mechanism of action
EPA, the active metabolite of E-EPA, like other omega-3 fatty acid based drugs, appears to reduce production of triglycerides in the liver, and to enhance clearance of triglycerides from circulating very low-density lipoprotein (VLDL) particles; the way it does that is not clear, but potential mechanisms include increased breakdown of fatty acids; inhibition of diglyceride acyltransferase which is involved in biosynthesis of triglycerides in the liver; and increased activity of lipoprotein lipase in blood.[4][6]...

Researchers initiated trials in 2019 to explore the mechanism of action of Vascepa:

This study is a Phase 1 pilot/feasibility mechanistic experiment to help clarify the mechanism of action of an EPA-rich fish oil preparation, icosapent ethyl, on lipid changes in statin-treated patients with residual triglyceridemia.

Full Title of Study: “Vascepa to Accelerate Lipoprotein Uptake and Elimination (VALUE): An Open-Label, Mechanistic, Randomized, Controlled, Single-Center Trial of AMR101 in Patients With Dyslipidemia”

https://trialbulletin.com/lib/entry/ct-03885661